Ex-vivo analysis shows that at the peak of the anti-melanoma effector response, melanoma specific Pmel-1 T cells are primed into competent effector cells (shown by surface phenotype, IFNγ secretion and lytic capacity in the periphery) but are unable to mediate tumor regression. The gene discussed is IFNG; the disease is melanoma.